These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21482493)

  • 21. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies.
    Wesolowski R; Peereboom D; Weiss P; Elson P; Thomas Budd G
    Invest New Drugs; 2010 Aug; 28(4):502-8. PubMed ID: 19434371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients.
    Magné N; Castadot P; Chargari C; Di Leo A; Philippson C; Van Houtte P
    Radiother Oncol; 2009 Jan; 90(1):116-21. PubMed ID: 19013659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
    Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
    Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
    Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
    Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
    Burstein HJ; Parker LM; Keshaviah A; Doherty J; Partridge AH; Schapira L; Ryan PD; Younger J; Harris LN; Moy B; Come SE; Schumer ST; Bunnell CA; Haldoupis M; Gelman R; Winer EP
    J Clin Oncol; 2005 Nov; 23(33):8340-7. PubMed ID: 16293865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide.
    Montella L; Addeo R; Guarrasi R; Cennamo G; Faiola V; Capasso E; Caraglia M; Del Prete S
    Eur J Cancer Care (Engl); 2010 Mar; 19(2):200-4. PubMed ID: 19552732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
    von Minckwitz G; Raab G; Caputo A; Schütte M; Hilfrich J; Blohmer JU; Gerber B; Costa SD; Merkle E; Eidtmann H; Lampe D; Jackisch C; du Bois A; Kaufmann M
    J Clin Oncol; 2005 Apr; 23(12):2676-85. PubMed ID: 15837982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide.
    Ip EJ; Lee-Ma A; Troxell LS; Chan J
    Am J Health Syst Pharm; 2008 Aug; 65(16):1552-5. PubMed ID: 18693211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.
    Zhang W; Jiang Z; Wang L; Li C; Xia J
    Med Oncol; 2015 May; 32(5):147. PubMed ID: 25820754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.
    Kosaka Y; Rai Y; Masuda N; Takano T; Saeki T; Nakamura S; Shimazaki R; Ito Y; Tokuda Y; Tamura K
    Support Care Cancer; 2015 Apr; 23(4):1137-43. PubMed ID: 25576433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer.
    Natoli C; Cianchetti E; Tinari N; Angelucci D; Grassadonia A; Zilli M; Ficorella C; Ricevuto E; Grossi S; De Tursi M; Carella C; Rispoli AI; Iacobelli S
    Ann Oncol; 2007 Jun; 18(6):1015-20. PubMed ID: 17369601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
    Lyman GH; Dale DC; Tomita D; Whittaker S; Crawford J
    Breast Cancer Res Treat; 2013 Jun; 139(3):863-72. PubMed ID: 23771731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant chemotherapy with TAC (docetaxel, doxorubicin, and cyclophosphamide) in patients with breast cancer--incidence of neutropenic fever outside clinical trials.
    Passos-Coelho JL; Esteves S; Vieira PA; Isidoro M; Ribeiro M; Oliveira J; Moreira AR
    Breast J; 2011; 17(5):539-41. PubMed ID: 21899649
    [No Abstract]   [Full Text] [Related]  

  • 36. Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer.
    Brain EG; Bachelot T; Serin D; Kirscher S; Graic Y; Eymard JC; Extra JM; Combe M; Fourme E; Noguès C; Rouëssé J;
    JAMA; 2005 May; 293(19):2367-71. PubMed ID: 15900007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support.
    Wolff AC; Jones RJ; Davidson NE; Jeter SC; Stearns V
    J Clin Oncol; 2006 May; 24(15):2392-4; author reply 2394-5. PubMed ID: 16710041
    [No Abstract]   [Full Text] [Related]  

  • 38. A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.
    Park KH; Sohn JH; Lee S; Park JH; Kang SY; Kim HY; Park IH; Park YH; Im YH; Lee HJ; Hong DS; Park S; Shin SH; Kwon HC; Seo JH
    Invest New Drugs; 2013 Oct; 31(5):1300-6. PubMed ID: 23677653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.
    Agiro A; Ma Q; Acheson AK; Wu SJ; Patt DA; Barron JJ; Malin JL; Rosenberg A; Schilsky RL; Lyman GH
    J Clin Oncol; 2016 Nov; 34(32):3872-3879. PubMed ID: 27646945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer.
    Schwartz J; Domchek SM; Hwang WT; Fox K
    Ann Oncol; 2005 Feb; 16(2):247-52. PubMed ID: 15668278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.